Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | April 23, 2019 | April 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 23, 2019 · Filed April 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 169,935 |
Ending reported balance
After 2019-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-23 · Exercise / conversion · Acquired 56,000 · Balance 225,935 Row 2 · 2019-04-23 · Sale · Disposed 56,000 · Balance 169,935 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 113,227 |
Reported balance
After 2019-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-23 · Exercise / conversion · Disposed 56,000 · Balance 113,227 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,698 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,698 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 53 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 53 F2: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019.
F2: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 50 | $46.93 | $2,346.55 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,638 Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 44,000 | $27.03 | $1,189,478.40 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 45,800 | $22.39 | $1,025,549.02 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 28,700 | $26.19 | $751,592.73 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 38,700 | $26.02 | $1,006,780.50 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 39,350 | $26.70 | $1,050,538.76 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,380 | $45.46 | $517,334.80 |
DisclosureSEC source: 0001179110-17-003670 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,138 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 182,242 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002922 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,242 Underlying: Common shares · 182,242 shares Expires 2027-02-16 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,748 on 02/17/2018, 60,747 on 02/17/2019, and 60,747 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 26,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002922 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,518 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 12,200 | $40.77 | $497,394.00 |
DisclosureSEC source: 0001179110-17-001518 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,167 Read SEC document |
| July 28, 2016 Filed Jul 29, 2016 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 41,500 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-16-028020 · edgar.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 41,500 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 28, 2016 Filed Jul 29, 2016 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,000 | $45.02 | $315,140.00 |
DisclosureSEC source: 0001179110-16-028020 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,967 Read SEC document |
| July 28, 2016 Filed Jul 29, 2016 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 34,500 | $45.00 | $1,552,500.00 |
DisclosureSEC source: 0001179110-16-028020 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,967 Read SEC document |
| July 28, 2016 Filed Jul 29, 2016 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 41,500 | $25.25 | $1,047,713.15 |
DisclosureSEC source: 0001179110-16-028020 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,340 | $39.26 | $52,609.74 |
DisclosureSEC source: 0001179110-16-020738 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,967 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 62 | $39.27 | $2,434.43 |
DisclosureSEC source: 0001179110-16-020738 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,307 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,039 | $39.52 | $396,741.28 |
DisclosureSEC source: 0001179110-16-020738 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,369 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 313,926 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019931 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,926 Underlying: Common shares · 313,926 shares Expires 2026-02-18 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 104,642 on 02/19/2017, 104,642 on 02/19/2018, and 104,642 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 35,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019931 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,408 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| August 18, 2015 Filed Aug 20, 2015 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $50.48 | $15,142.50 |
DisclosureSEC source: 0001179110-15-012422 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,601 Read SEC document |
| August 18, 2015 Filed Aug 20, 2015 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $50.47 | $65,613.60 |
DisclosureSEC source: 0001179110-15-012422 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,901 Read SEC document |
| August 18, 2015 Filed Aug 20, 2015 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $50.47 | $50,470.00 |
DisclosureSEC source: 0001179110-15-012422 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,201 Read SEC document |
| August 18, 2015 Filed Aug 20, 2015 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $50.46 | $5,046.20 |
DisclosureSEC source: 0001179110-15-012422 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,201 Read SEC document |
| August 18, 2015 Filed Aug 20, 2015 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,396 | $50.46 | $524,582.16 |
DisclosureSEC source: 0001179110-15-012422 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,301 Read SEC document |
| August 11, 2015 Filed Aug 13, 2015 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 41,500 | $0.00 Strike: $21.22 | $0.00 |
DisclosureSEC source: 0001179110-15-012082 · edgar.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 41,500 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 11, 2015 Filed Aug 13, 2015 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 28,404 | $50.66 | $1,438,946.64 |
DisclosureSEC source: 0001179110-15-012082 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,697 Read SEC document |
| August 11, 2015 Filed Aug 13, 2015 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 41,500 | $21.22 | $880,605.10 |
DisclosureSEC source: 0001179110-15-012082 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,459 | $47.61 | $545,562.99 |
DisclosureSEC source: 0001179110-15-004047 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,601 Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 169,227 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003339 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,227 Underlying: Common shares · 169,227 shares Expires 2025-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 56,409 on 2/20/16, 56,409 on 2/20/17, and 56,409 on 2/20/18. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003339 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,060 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| September 18, 2014 Filed Sep 19, 2014 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,400 | $0.00 Strike: $23.22 | $0.00 |
DisclosureSEC source: 0001179110-14-014360 · edgar.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 17,400 shares Expires 2015-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 18, 2014 Filed Sep 19, 2014 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 14,500 | $0.00 Strike: $22.27 | $0.00 |
DisclosureSEC source: 0001179110-14-014360 · edgar.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 14,500 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 18, 2014 Filed Sep 19, 2014 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 23,619 | $43.38 | $1,024,592.22 |
DisclosureSEC source: 0001179110-14-014360 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,045 Read SEC document |
| September 18, 2014 Filed Sep 19, 2014 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,400 | $23.22 | $404,000.16 |
DisclosureSEC source: 0001179110-14-014360 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2014 Filed Sep 19, 2014 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 14,500 | $22.27 | $322,871.50 |
DisclosureSEC source: 0001179110-14-014360 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 13,414 | $39.79 | $533,743.06 |
DisclosureSEC source: 0001179110-14-004306 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,764 Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 134,741 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003626 · edgar.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,741 Underlying: Common Shares · 134,741 shares Expires 2024-02-20 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,914 on 2/21/2015, 44,913 on 2/21/2016, and 44,914 on 2/21/2017. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon Shares without par value | 22,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-003626 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,178 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| November 08, 2013 Filed Nov 8, 2013 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,227 | $0.00 Strike: $19.72 | $0.00 |
DisclosureSEC source: 0001179110-13-016351 · edgar.xml · derivative · entry 10 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,227 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 08, 2013 Filed Nov 8, 2013 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 642 | $37.64 | $24,164.88 |
DisclosureSEC source: 0001179110-13-016351 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,169 Read SEC document |
| November 08, 2013 Filed Nov 8, 2013 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,227 | $19.72 | $24,191.90 |
DisclosureSEC source: 0001179110-13-016351 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2013 Filed Nov 8, 2013 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,558 | $0.00 Strike: $25.17 | $0.00 |
DisclosureSEC source: 0001179110-13-016351 · edgar.xml · derivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 7,558 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 07, 2013 Filed Nov 8, 2013 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,908 | $0.00 Strike: $25.52 | $0.00 |
DisclosureSEC source: 0001179110-13-016351 · edgar.xml · derivative · entry 8 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,908 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 07, 2013 Filed Nov 8, 2013 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,466 | $37.59 | $393,416.94 |
DisclosureSEC source: 0001179110-13-016351 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,584 Read SEC document |
| November 07, 2013 Filed Nov 8, 2013 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,558 | $25.17 | $190,265.85 |
DisclosureSEC source: 0001179110-13-016351 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2013 Filed Nov 8, 2013 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,908 | $25.52 | $74,226.12 |
DisclosureSEC source: 0001179110-13-016351 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2013 Filed Mar 2, 2013 00:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,974 | $34.26 | $410,229.24 |
DisclosureSEC source: 0001179110-13-003899 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,584 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 666 | $34.80 | $23,177.47 |
DisclosureSEC source: 0001179110-13-003138 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,558 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,400 | $34.80 | $83,524.80 |
DisclosureSEC source: 0001179110-13-003138 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,224 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,269 | $35.08 | $290,076.52 |
DisclosureSEC source: 0001179110-13-003138 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,624 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.